Abstract
Panax notoginseng (P.notoginseng) and its components are used as traditional Chinese medicine for cardiovascular disease, although studies concerning the anti-metastatic properties of these compounds are limited. The goal of this study was to investigate the effects of notoginsenosideR1(NGR1), an important compound derived from P.notoginseng, on the metastasis of human colorectal cancer(CRC). The migratory, invasive, and adhesive abilities of cultured human CRC cells (HCT-116) treated with NGR1 and expression of metastasis‑associated regulatory molecules were assessed. The migratory and invasive abilities of the HCT-116 cells were reduced after treatment with 75, 150 or 300µM NGR1 for 24h. When HCT-116 cells were incubated with 150 or 300µM NGR1 for 24h, matrix metalloproteinase(MMP)-9 expression was reduced compared with that of the control group. In the adhesion reaction assays, treatment with 150 or 300µM NGR1 led to significantly decreased adhesion of the HCT-116 cells to endothelial cells (EA.hy926 cells). Levels of integrin-1 protein were significantly decreased in the HCT-116 cells following treatment with 75, 150 or 300µM NGR1, and levels of E-selectin and intercellular adhesion molecule1(ICAM-1) proteins were significantly decreased in the EA.hy926 cells treated with 75, 150 or 300µM NGR1. Scanning electron microscopy examination indicated that HCT-116 cells treated with lipopolysaccharide(LPS) combined with 300µM NGR1 exhibited a less flattened and retracted shape compared with cells treated with LPS alone, and this change in shape is characteristic of extravasation. Additionally, the transepithelial electrical resistance of the EA.hy926 endothelial cell monolayer increased after incubation with 150 or 300µM NGR1 for 24h. Overall, these results demonstrated the anti-metastatic properties of 150 or 300µM NGR1, a compound that affects CRC metastasis by inhibiting cell migration, invasion, and adhesion and by regulating expression of metastasis-associated signalling molecules.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
